(Q41610311)

English

Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUES

scientific article published on 9 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUES (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Scott

1

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

L Gilles

2

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

M Fu

3

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

E Brohan

4

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

C Panter

5

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

R Arbuckle

6

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

W Jessner

7

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

M Beumont

8

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

publication date

9 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

639-650

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Chronic HCV infection: epidemiological and clinical relevance

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Depression, anemia and health-related quality of life in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Emotional distress in chronic hepatitis C patients not receiving antiviral therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Health-related quality of life in chronic liver disease: the impact of type and severity of disease

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Health-state utilities in liver disease: a systematic review.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D).

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The burden of untreated hepatitis C virus infection: a US patients' perspective

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

A comparison of health utility measures for the evaluation of multiple sclerosis treatments

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Health-State Utilities and Quality of Life in Hepatitis C Patients

1 reference

https://api.crossref.org/works/10.1111%2FJVH.12365

21 January 2018

Identifiers

10.1111/JVH.12365

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41610311&oldid=1562842037"